Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas

• Published in: Biomedicines 2022-08, Vol.10 (8), p.2051
• Main Authors: Issa, Peter P., Omar, Mahmoud, Buti, Yusef, Issa, Chad P., Chabot, Bert, Carnabatu, Christopher J., Munshi, Ruhul, Hussein, Mohammad, Aboueisha, Mohamed, Shama, Mohamed, Corsetti, Ralph L., Toraih, Eman, Kandil, Emad
• Format: Article
• Language: English
• Subjects: Biopsy; Decision making; Hashimoto’s thyroiditis; Hypothyroidism; lymph node metastasis; Lymph nodes; Lymphatic system; Medical prognosis; Metastases; Metastasis; Mutants; Mutation; Papillary thyroid cancer; Papillary thyroid carcinoma; Patients; protective factor; risk factor; Thyroid cancer; Thyroidectomy; Thyroiditis; Tumors
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10082051

Hashimoto’s thyroiditis (HT) (autoimmune thyroiditis) is a clinicopathological entity associated with chronic lymphocytic infiltration resulting in hypothyroidism. HT is a double-edged sword that increases the risk of papillary thyroid cancer (PTC), yet it serves as a protective factor for PTC progression. BRAF mutation in PTCs is associated with rapid cell growth, aggressive tumor characteristics, and higher mortality rates. Here, we aimed to analyze the influence of HT in patients with PTCs and its effect on lymph node metastasis (LNM) in BRAF mutant tumors. Adults diagnosed with PTC between 2008 and January 2021 were retrospectively included. A total of 427 patients, 128 of whom had underlying HT, were included. The HT group had significantly higher rates of microcarcinoma (49.2% vs. 37.5%, p = 0.025) and less lateral LNM (8.6% vs. 17.1%, p = 0.024). Interestingly, BRAF-mutated PTCs were found to have significantly less overall LNM (20.9% vs. 51%, p = 0.001), central LNM (25.6% vs. 45.1%, p = 0.040) and lateral LNM (9.3% vs. 29.4%, p = 0.010) in patients with HT when compared to those without underlying HT. HT was found to be an independent protective predictor of overall and lateral LNM. Altogether, HT was able to neutralize the effect of BRAF mutation and was determined to be an independent protective factor against LNM. Specifically, our work may influence treatment-aggressiveness decision making for endocrinologists, oncologists and surgeons alike.